Amneal to Acquire Kashiv BioSciences

Amneal Pharmaceuticals has reached a definitive agreement to acquire Kashiv BioSciences. The acquisition is intended to enhance Amneal’s capabilities in the biosimilars sector by building a fully integrated global platform, aimed at broadening access to cost-effective biologic medicines. This move is significant as it aligns with growing opportunities in the biosimilars market, spurred by the increasing expiration of biologic drug patents.

The terms of the deal were not disclosed. However, the strategic importance lies in the integration of Kashiv's robust research, development, and manufacturing expertise with Amneal’s commercial distribution network. Kashiv, based in Piscataway, New Jersey, and operating in both the United States and India, brings to the table a wide range of capabilities, including clinical trials, regulatory processes, and intellectual property management. Amneal, headquartered in Bridgewater, New Jersey, has a diverse portfolio covering generics, specialty products, and biosimilars, making it a formidable player in the realm of affordable medicines.

The acquisition seeks to leverage Kashiv’s capabilities to improve manufacturing efficiency and streamline the development of biosimilars, further enhancing Amneal's position both in the U.S. and internationally. Given the projected increase in biosimilar adoption, particularly as more biologic drugs lose exclusivity, the deal aims to firmly position Amneal as a leader in this rapidly expanding market. The integration is expected to deliver a steady pipeline of biosimilar launches, promising to expand patient access to affordable treatments.

This acquisition capitalizes on a longstanding relationship between Amneal and Kashiv, effectively consolidating their strengths at a time when the biosimilars sector is ripe for growth. The move is a strategic component of Amneal’s ambition to establish itself as a leading diversified biopharmaceutical entity, enabling it to adapt to shifting market dynamics marked by increasing demand for cheaper biologic drugs.

The transaction requires Amneal shareholder approval, as well as regulatory clearances and standard closing conditions. The closure of the deal is anticipated in the second half of 2026, marking a potential reshaping of the competitive landscape within the biosimilars industry and potentially setting a new benchmark in the provision of affordable biologic medicines globally.